{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-043794","form_type":"8-K","ticker":"QCLS","cik":"0001321834","company_name":"Q/C TECHNOLOGIES, INC.","filed_at":"2023-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.601126+00:00","generated_at":"2026-06-07T16:54:49.682257+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MyMD Pharma gains FDA clearance for Phase 2 trial of oral MYMD-1 in rheumatoid arthritis","bullets":["FDA cleared IND for Phase 2 trial of oral MYMD-1 (TNF-α inhibitor) in rheumatoid arthritis.","Trial planned for Q1 2024; will enroll ~60 patients with active RA at 1050 mg oral dose.","Preclinical data: MYMD-1 reduced disease severity by 47% vs 37% for Enbrel (etanercept).","MYMD-1 could become first FDA-approved orally administered TNF-α inhibitor for RA.","RA affects ~1.5M Americans with annual societal cost estimated over $40 billion."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-043794","json":"https://secwatch.observer/filing/0001493152-23-043794.json","markdown":"https://secwatch.observer/filing/0001493152-23-043794.md","text":"https://secwatch.observer/filing/0001493152-23-043794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223043794/0001493152-23-043794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1321834/000149315223043794/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T16:54:49.682257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}